Acerand Therapeutics Updates the Phase I/II Study of ACE-106 (ACE-86225106), a highly selective and Potentially Best-in-class PARP1 Inhibitor, in Advanced Solid Tumors Acerand Therapeutics Reports ...
Despite growing awareness of the negative health outcomes associated with adverse childhood experiences (ACEs), concerns remain. Recent research underscores troubling trends and the need for greater ...
Dental anxiety is a widespread issue that affects countless people globally, causing them to avoid dental care and suffer from poor oral health. A study by the Division of Oral and Maxillofacial ...
Two-thirds of US adults report adverse childhood experiences: CDC study reveals troubling prevalence
In the recent Centers for Disease Control and Prevention's (CDC) Morbidity and Mortality Weekly Report (MMWR), researchers provided adverse childhood experience (ACE) prevalence estimates for adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results